Taiwan Biomaterial Co., Ltd. (TPEX:6649)

Market Cap	1.70B +14.2%
Revenue (ttm)	203.27M +142.7%
Net Income	56.88M
EPS	1.35
Shares Out	42.00M
PE Ratio	30.03
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	104,722
Average Volume	135,170
Open	40.15
Previous Close	40.75
Day's Range	40.00 - 41.10
52-Week Range	29.65 - 80.40
Beta	0.80
RSI	20.61
Earnings Date	Mar 13, 2026

About Taiwan Biomaterial

Taiwan Biomaterial Co., Ltd. engages in the development and sale of implantable medical devices in Taiwan. It offers Foamagen, a foamagen dura substitute; stroke thrombus negative pressure removal catheter system comprising suction and removal of cerebrovascular embolism blood clot for the pump system, and nickel-titanium guidewire for guiding cerebral vascular surgery; tissue repair and regeneration products for the treatment of early osteoarthritis; and CDMO. The company was founded in 1921 and is based in Zhubei, Taiwan.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1921
• Employees: 35
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6649

Financial Performance

In 2024, Taiwan Biomaterial's revenue was 96.57 million, an increase of 32.59% compared to the previous year's 72.84 million. Losses were -1.73 million, -82.90% less than in 2023.